Blockchain Registration Transaction Record

OS Therapies Advances Breakthrough Osteosarcoma Treatment Toward Approval

OS Therapies reports 75% 2-year survival in osteosarcoma trial, plans regulatory filings for OST-HER2 with FDA and UK MHRA by year-end 2025.

This development represents a potential breakthrough for osteosarcoma patients, particularly those with recurrent pulmonary metastases who currently face limited treatment options and poor survival rates. The 75% two-year survival rate demonstrated by OST-HER2 dramatically outperforms historical controls at 40%, suggesting this could become a new standard of care for a devastating pediatric and young adult cancer. For investors, the progress toward regulatory submissions and planned spin-off of OS Animal Health creates multiple value catalysts, while the broader oncology field gains insights into successful regulatory strategies using historical controls and real-world evidence. The treatment's success could also validate the listeria platform technology for other cancer applications, potentially accelerating development of additional immunotherapies.